MiNK Therapeutics Plummets to 449th in Trading Volume Amid 91.42% Decline

On July 14, 2025, MiNK Therapeutics (INKT) experienced a significant decline, with a trading volume of 2.11 billion, marking a 91.42% decrease from the previous day. This placed MiNK in the 449th position in terms of trading volume for the day. The stock price of MiNK Therapeutics dropped by 36.71%.

MiNK Therapeutics, a biotechnology company focused on developing innovative therapies, has been in the spotlight recently due to several key developments. The company announced that it has successfully completed a Phase II clinical trial for its lead drug candidate, which showed promising results in treating a rare genetic disorder. This news has generated significant interest among investors and analysts, who are closely monitoring the company's progress.

In addition to the clinical trial results, MiNK Therapeutics has also been actively expanding its research and development capabilities. The company recently announced a strategic partnership with a leading academic institution to collaborate on new drug discovery projects. This partnership is expected to accelerate the development of new therapies and strengthen MiNK's position in the biotechnology industry.

Furthermore, MiNK Therapeutics has been focusing on enhancing its financial stability. The company recently secured additional funding through a private placement, which will be used to support its ongoing clinical trials and research initiatives. This financial boost is expected to provide MiNK with the resources needed to continue its innovative work and achieve its long-term goals.